Article
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer.
BMC cancer - 23 Jan 2023
Harada Yohei, Sato Akemi, Nakamura Hideaki, Kai Keita, Kitamura Sho, Nakamura Tomomi, Kurihara Yuki, Ikeda Sadakatsu, Sueoka Eisaburo, Kimura Shinya, Sueoka-Aragane Naoko
Abstract excerpt
BACKGROUND: Precision medicine with gene panel testing based on next-generation sequencing for patients with cancer is being used increasingly in clinical practice. HER2, which encodes the human epidermal growth factor receptor 2 (HER2), is a potentially important driver gene. However, therapeutic strategies aimed at mutations in the HER2 extracellular domain have not been clarified. We therefore investigated the...
Topics
Join the communities discussing this publication.